Working to Eradicate Gynecologic Cancers

William E. Brady, PhD

Study Biostatistician
Gynecologic Oncology Group Statistical and Data Center
Elm and Carlton Streets
Buffalo, NY
USA 14263

Papers:
51 A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study